samedan logo
 
 
 
spacer
home > ebr > autumn 2001 > putting function first in proteomics
PUBLICATIONS
European Biopharmaceutical Review

Putting Function First in Proteomics

The last few years have seen an enormous revival in protein science under the relatively new name of 'proteomics'. The term proteome was coined by Marc Wilkins in 1994, and is used to describe the entire protein complement of the genome. This can be further defined as the protein complement at any point in time - underlining the fact that proteins are complex, dynamic systems constantly changing in number and structure in response to physiological and environmental stimuli. Unlike traditional protein biochemistry, the science of proteomics generally refers to large-scale protein studies involving the high throughput screening and identification of novel proteins. A key aim of proteomics is to uncover the function of novel proteins - so providing possible new targets for drug intervention. Surface plasmon resonance (SPR) technology not only provides a means of isolating novel proteins, but also of uncovering their functional properties.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Stefan Löfås, Vice President and Chief Scientific Officer at Biacore AB

Stefan Löfås holds a PhD and BSc in Organic Chemistry. He has extensive technical and scientific experience in the development and commercialisation of bioanalytical instrumentation at Biacore AB, having worked for the company since 1985. He has been deeply involved in the development of Biacore's sensor chip chemistry and applications. Recently appointed Chief Scientific Officer, he has responsibility for technical development projects, external scientific collaborations and technical aspects on the IPR portfolio. Prior to this role, Dr Löfås was Director of Biacore's Biochemistry and Chemistry department within R&D.
spacer
Stefan Löfås
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Distributed Control System Facilitates Expansion for New Drugs Produced by Contract Manufacturing Organisation

Combatting the pandemic has highlighted the importance of the partnership between biopharma organizations and the contract manufacturing organizations (CMOs) that must flexibly handle outsourced production, which can come suddenly and often must quickly be ramped up.
More info >>

White Papers

What Your Clinical Study Design Reveals About Your Clinical Packaging Needs

PCI Pharma Services

As the cost and complexities of drug development increase, so do the challenges of global clinical trials. Today’s sponsors must be able to manage and coordinate multiple resources, processes, and locations with speed and accuracy to design effective and efficient clinical trials. Securing a stable supply chain to deal with the uncertainties of clinical trials is critical. One misstep can have a profound impact not only on the cost and time of your trial but also on its overall success.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement